A larger phase III randomized trial included 202 FLT3-mutant AML investigating sorafenib maintenance post allo-HCT; 100 patients were treated in the sorafenib arm versus 102 in the control arm. The gene discussed is FLT3; the disease is acute myeloid leukemia.